PMID- 19760065
OWN - NLM
STAT- MEDLINE
DCOM- 20100622
LR  - 20220223
IS  - 0065-2598 (Print)
IS  - 0065-2598 (Linking)
VI  - 647
DP  - 2009
TI  - Targeting TNF for Treatment of Cancer and Autoimmunity.
PG  - 37-51
LID - 10.1007/978-0-387-89520-8_3 [doi]
AB  - Tumor necrosis factor-alpha (TNF-alpha) was first isolated two decades ago as a 
      macrophageproduced protein that can effectively kill tumor cells. TNF-alpha is 
      also an essential component of the immune system and is required for 
      hematopoiesis, for protection from bacterial infection and for immune 
      cell-mediated cytotoxicity. Extensive research, however, has revealed that 
      TNF-alpha is one of the major players in tumor initiation, proliferation, 
      invasion, angiogenesis and metastasis. The proinflammatory activities link 
      TNF-alpha with a wide variety of autoimmune diseases, including psoriasis, 
      inflammatory bowel disease, rheumatoid arthritis, systemic sclerosis, systemic 
      lupus erythematosus, multiple sclerosis, diabetes and ankylosing spondylitis. 
      Systemic inhibitors of TNF such as etanercept (Enbrel) (a soluble TNF receptor) 
      and infliximab (Remicade) and adalimumab (Humira) (anti-TNF antibodies) have been 
      approved for the treatment inflammatory bowel disease, psoriasis and rheumatoid 
      arthritis. These drugs, however, exhibit severe side effects and are expensive. 
      Hence orally active blockers of TNF-alpha that are safe, efficacious and 
      inexpensive are urgently needed. Numerous products from fruits, vegetable and 
      traditional medicinal plants have been described which can suppress TNF 
      expression and TNF signaling but their clinical potential is yet uncertain.
FAU - Sethi, Gautam
AU  - Sethi G
AD  - Cytokine Research Laboratory, Department of Experimental Therapeutics, The 
      University of Texas MD Anderson Cancer Center, Unit 143, 1515 Holcombe Boulevard, 
      Houston, Texas, 77030, USA.
FAU - Sung, Bokyung
AU  - Sung B
FAU - Kunnumakkara, Ajaikumar B
AU  - Kunnumakkara AB
FAU - Aggarwal, Bharat B
AU  - Aggarwal BB
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Adv Exp Med Biol
JT  - Advances in experimental medicine and biology
JID - 0121103
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Biological Products)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Receptors, Tumor Necrosis Factor)
RN  - 0 (Tumor Necrosis Factor Inhibitors)
RN  - 0 (Tumor Necrosis Factors)
RN  - B72HH48FLU (Infliximab)
RN  - FYS6T7F842 (Adalimumab)
RN  - OP401G7OJC (Etanercept)
SB  - IM
MH  - Adalimumab
MH  - Animals
MH  - Anti-Inflammatory Agents/therapeutic use
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - *Autoimmunity
MH  - Biological Products/therapeutic use
MH  - Etanercept
MH  - Humans
MH  - Immunoglobulin G/therapeutic use
MH  - Infliximab
MH  - Neoplasms/*drug therapy/immunology
MH  - Receptors, Tumor Necrosis Factor/therapeutic use
MH  - *Tumor Necrosis Factor Inhibitors
MH  - Tumor Necrosis Factors/immunology
RF  - 159
EDAT- 2009/09/18 06:00
MHDA- 2010/06/23 06:00
CRDT- 2009/09/18 06:00
PHST- 2009/09/18 06:00 [entrez]
PHST- 2009/09/18 06:00 [pubmed]
PHST- 2010/06/23 06:00 [medline]
AID - 10.1007/978-0-387-89520-8_3 [doi]
PST - ppublish
SO  - Adv Exp Med Biol. 2009;647:37-51. doi: 10.1007/978-0-387-89520-8_3.